Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study
Journal of Clinical Apheresis · 2025
DOI: 10.1002/jca.70072 ↗At a glance
Randomisierte kontrollierte Studie in Journal of Clinical Apheresis, 2025. Written by Jameel Abdulrehman and 6 co-authors. Institution: Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada. Major MEDLINE topics: Anemia, Sickle Cell, Central Venous Catheters, Venous Thromboembolism, Rivaroxaban. 9 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Paul B. Helliwell Foundation.
Topics: Thromboseprophylaxe
Abstract (original language)
Individuals with sickle cell disease (SCD) often require central venous catheter (CVC) use; however, this is associated with a high incidence of venous thromboembolism (VTE). We conducted a pilot randomized controlled trial (RCT) to assess if it is feasible and safe to conduct an adequately powered RCT comparing rivaroxaban to placebo as thromboprophylaxis in adult SCD participants with CVC. In this pilot investigator‐initiated, double‐blinded, multi‐center RCT, we assessed feasibility outcomes to explore if a full RCT is possible, and also exploratory outcomes of thrombosis and bleeding. THIS pilot trial was closed prematurely due to slow recruitment, lack of funding, and non‐feasibility of the complete trial. Of 21 participants who met eligibility criteria, 4 were recruited into the study. Adherence to study procedures was 100% and loss to follow‐up was 0%. One participant was noted to have a VTE during follow‐up, but of unknown chronicity. Another participant developed a new VTE post‐randomization, but prior to starting study drug. No major or clinically relevant bleeding events occurred during study follow‐up. Challenges in running the study were largely due to a limited eligible population, and low participation interest in study involvement. Trial Registration: ClinicalTrials.gov identifier: NCT05033314
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada.
- Division of Hematology, Department of Medicine, Centre Hospitalier de L'université de Montréal (CHUM), Montreal, Canada.
- Toronto General Hospital Research Institute, Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
- Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada.
- Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada.
- Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Canada.
ORCID profiles: Jameel Abdulrehman, Stéphanie Forté, George Tomlinson, Ziad Solh, Lauren Bolster, Haowei Linda Sun, Kevin H M Kuo
Funding
- Paul B. Helliwell Foundation
Cite
APA
Abdulrehman, J., Forté, S., Tomlinson, G., Solh, Z., Bolster, L., Sun, H. L., & Kuo, K. H. M. (2025). Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70072
Vancouver
Abdulrehman J, Forté S, Tomlinson G, Solh Z, Bolster L, Sun HL, et al. Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70072
BibTeX
@article{Abdulrehman2025,
author = {Abdulrehman, Jameel and Forté, Stéphanie and Tomlinson, George and Solh, Ziad and Bolster, Lauren and Sun, Haowei Linda and Kuo, Kevin H M},
title = {Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study},
journal = {Journal of Clinical Apheresis},
year = {2025},
doi = {10.1002/jca.70072}
}
EUVIMED